At Work: Center for Experimental Therapeutics Chair David Scheinberg
A second-generation physician-scientist, David Scheinberg specializes in caring for patients with leukemia — and developing new ways to treat it.
Innovative Partnership Will Speed Drug Discovery and Development
Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients.
Scientists ID Antibody That Might Boost Cancer Therapy
Physician-scientist David Scheinberg discussed his discovery of a unique monoclonal antibody, a molecule that can be engineered to target specific prot...
In the Lab
New Molecule Targets Proteins Inside Cancer Cells
Scientists from Memorial Sloan Kettering have collaborated on the discovery of a unique monoclonal antibody, called ESK1, that appears to be effective at targeting and destroying several types of cancer cells.
The Cancer Bomb: How Nuclear Sludge Gave Birth to an Experimental Leukemia Drug
David Scheinberg, Chair of the Molecular Pharmacology and Chemistry Program, discussed his research on actinium and its cancer-fighting abilities....
David Scheinberg Receives 2012 Emil J. Freireich Award
The MD Anderson Cancer Center presented its annual award to Dr. Scheinberg in recognition of his pioneering work in developing chemotherapeutic agents for leukemia and other cancers.
New Nanotechnology Center Combines Cutting-Edge Science with Memorial Sloan Kettering's Expertise in Patient Care
To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center.
Study Answers Important Question about Using Carbon Nanotubes in Medicine
A multicenter study led by Memorial Sloan Kettering researchers has answered an important question about the safety of using carbon nanotubes in medicine.
David Scheinberg Elected to the Association of American Physicians
David A. Scheinberg has been elected a member of the prestigious Association of American Physicians (AAP).
Four MSK Researchers Receive 2020 Outstanding Investigator Award from the National Cancer Institute
Four MSK researchers out of 15 winners nationwide were named recipients of the prestigious award. They will each receive a grant of up to $600,000 per year for seven years to support their research in cancer.